Nephrocare Health Services Limited
NSE: NEPHROPLUSHealthcare Service Provider
Share price
₹626.95
-2.28% close of 8 Oct 2026
Business score
How strong the business is, in one number. The parts behind it are in Pro.
68
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹6,270 Cr
P/E ratio
73.7
P/B ratio
5.6
ROCE
15.3%
ROE
8.8%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 29.7% a year against a sector median of 13.1% — 16.7 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 0.7 times its growth rate, on earnings growth of 103%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Nephrocare Health Services Limited — this one | 103%/yr | 73.7× | — |
| Dr. Lal Path Labs Ltd. | 30%/yr | 56.7× | ₹1.9 |
| Vijaya Diagnostic Centre Limited | 24%/yr | 76.5× | ₹3.2 |
| Metropolis Healthcare Limited | 11%/yr | 51.6× | ₹4.7 |
| Thyrocare Technologies Limited | 36%/yr | 44.3× | ₹1.2 |
| Krsnaa Diagnostics Limited | 18%/yr | 17.5× | ₹0.97 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Healthcare Service Provider), it ranks 10 of 12 on returns, 1 of 11 on growth, 10 of 12 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 15.3% on capital, ahead of 17% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Roughly — Over the last five years it made ₹465 crore of cash from the business and spent about as much on plant and equipment. And the profit is real: of every 100 rupees it reported over 6 years, about 338 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back faster than it used to: it went from being waiting 55 days for its cash to waiting 42 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
7 of 9 checks clear · 78%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue grew 23.7% year-on-year, above the 15% to 20% medium-term growth guide.
Announced 11 Aug 2026 · Consolidated · Unaudited
Revenue
₹282 Cr
Revenue vs last quarter
+5.9%
Net profit
₹32 Cr
Profit vs last quarter
+6.6%
Net margin
11.3%
EPS
₹3.19
Earnings call transcript · 12 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹6,270 Cr
- Prev close
- ₹626.95
- 52w High
- ₹782
- 52w Low
- ₹446
- Enterprise value
- ₹5,924 Cr
- Beta
- 0.7
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 5.2%
- PEG ratio
- 0.7
- P/E ratio
- 73.7
- P/B ratio
- 5.6
- EV / EBITDA
- 25.1
- Industry P/E
- 44.1
- ROCE
- 15.3%
- ROCE 5y average
- 6.8%
- ROE
- 8.8%
- Debt / Equity
- 0.1
- Interest coverage
- 2.6
- Dividend yield
- 0.0%
- ROE 3y average
- 10.0%
- ROE last year
- 9.0%
Annual P&L
- Annual revenue
- ₹999 Cr
- Annual profit
- ₹77 Cr
- Operating margin
- 23.0%
- Net profit margin
- 7.7%
- EBITDA margin
- 22.5%
- Sales growth 3y
- 31.7%
- Sales growth 5y
- 28.4%
- Profit growth 3y
- 103.0%
- Profit growth 5y
- 162.0%
- EPS
- ₹7.7
- Sales growth TTM
- 32.0%
- Profit growth TTM
- 12.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹282 Cr
- Profit latest quarter
- ₹32 Cr
- YoY quarterly sales growth
- 23.7%
- YoY quarterly profit growth
- 33.3%
- OPM latest quarter
- 21.4%
Balance Sheet
- Book Value
- ₹112
- Face Value
- ₹2.0
- Total debt
- ₹80 Cr
- Total cash
- ₹255 Cr
- Borrowings
- ₹80 Cr
- Reserves / Equity
- 54.8
Cash Flow
- Operating cash flow
- ₹233 Cr
- Free cash flow
- ₹113 Cr
- FCF yield
- 0.8%
- Net cash flow
- -₹2 Cr
Shareholding
- Promoter holding
- 63.9%
- FII holding
- 8.8%
- DII holding
- 9.1%
- Public holding
- 18.3%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | 1,914.30 | 57.1 | 32,131 | 0.73 | 170.5 | 28.0 | 797.7 | 19.1 | 28.0 |
| Vijaya Diagnost. | 1,445.55 | 79.4 | 14,889 | 0.14 | 53.1 | 37.6 | 231.0 | 22.8 | 20.5 |
| Metropolis Healt | 532.85 | 53.1 | 11,054 | 0.37 | 56.9 | 25.8 | 450.2 | 16.6 | 17.8 |
| Thyrocare Tech. | 505.05 | 44.4 | 8,039 | 1.82 | 51.3 | 34.1 | 240.0 | 24.3 | 35.4 |
| Nephrocare Health Services | 625.85 | 74.0 | 6,294 | 0.00 | 32.0 | 34.9 | 281.8 | 23.7 | 15.3 |
| Krsnaa Diagnost. | 535.85 | 17.6 | 1,738 | 0.37 | 15.8 | -19.1 | 210.7 | 19.9 | 12.7 |
| Suraksha Diagno. | 312.75 | 45.5 | 1,629 | 0.16 | 12.9 | 38.4 | 87.7 | 20.8 | 17.3 |
| Median | 319.95 | 32.4 | 1,124 | 0.00 | 11.0 | 28.0 | 95.2 | 19.1 | 20.5 |
Competes with: 3B Blackbio Dx Limited, Dr. Lal Path Labs Ltd., Gaudium IVF and Women Health Limited, Health X Platform Limited, Krsnaa Diagnostics Limited, Metropolis Healthcare Limited, One Global Service Provider Limited, Pramodini Medicare Limited, Sastasundar Ventures Limited, Suraksha Diagnostic Limited, Thyrocare Technologies Limited, Vijaya Diagnostic Centre Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 |
| Material Cost | 59 | 60 | 62 | ||||
| Change in Inventories | 0 | 0 | 0 | ||||
| Purchases of Stock-in-Trade | 0 | 0 | 0 | ||||
| Employee Cost | 43 | 46 | 48 | ||||
| Other Expenses | 97 | 106 | 108 | ||||
| Operating Profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 |
| OPM % | 22 | 23 | 21 | 26 | 23 | 19 | 21 |
| Other Income | 5 | 4 | 7 | 4 | 3 | 12 | 7 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | ||||
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 |
| Profit before tax | 26 | 30 | 29 | -1 | 36 | 33 | 41 |
| Tax % | 24 | 17 | 17 | 1,427 | 11 | 9 | 22 |
| Net Profit | 20 | 25 | 24 | -9 | 32 | 30 | 32 |
| EPS in Rs | 97 | 119 | 13 | -5.24 | 3.21 | 3.03 | 3.19 |
| Diluted EPS in Rs | 3.35 | 2.96 | 3.11 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 286 | 318 | 437 | 566 | 756 | 999 | 1,053 |
| Expenses | 248 | 302 | 389 | 465 | 589 | 774 | 817 |
| Material Cost | 227 | ||||||
| Change in Inventories | 0 | ||||||
| Purchases of Stock-in-Trade | 0 | ||||||
| Employee Cost | 172 | ||||||
| Other Expenses | 373 | ||||||
| Operating Profit | 37 | 16 | 49 | 101 | 167 | 225 | 236 |
| OPM % | 13 | 5 | 11 | 18 | 22 | 23 | 22 |
| Other Income | 5 | 10 | 6 | 8 | 14 | 23 | 26 |
| Exceptional items (within Other Income) | 0 | ||||||
| Interest | 7 | 10 | 16 | 20 | 21 | 60 | 56 |
| Depreciation | 34 | 42 | 47 | 56 | 72 | 91 | 96 |
| Profit before tax | 1 | -27 | -9 | 33 | 87 | 97 | 110 |
| Tax % | 31 | -21 | 37 | -6 | 23 | 21 | |
| Net Profit | 1 | -21 | -12 | 35 | 67 | 77 | 85 |
| EPS in Rs | 3.40 | -107 | -59 | 170 | 322 | 7.66 | 4.19 |
| Diluted EPS in Rs | 8.10 | ||||||
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- 28%
- 3 years
- 32%
- TTM
- 32%
Compounded profit growth
- 10 years
- —
- 5 years
- 162%
- 3 years
- 103%
- TTM
- 12%
Return on equity
- 10 years
- —
- 5 years
- 6%
- 3 years
- 10%
- Last year
- 9%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 1.77 | 20 |
| Reserves | 245 | 391 | 384 | 409 | 579 | 1,096 |
| Borrowings | 140 | 119 | 200 | 271 | 261 | 80 |
| Other Liabilities | 42 | 59 | 81 | 124 | 153 | 271 |
| Minority Interest | 0 | |||||
| Total Liabilities | 428 | 571 | 666 | 806 | 994 | 1,467 |
| Fixed Assets | 192 | 205 | 239 | 356 | 396 | 517 |
| CWIP | 2 | 43 | 34 | 1 | 6 | 6 |
| Investments | 0 | 0 | 0 | 0 | 51 | 178 |
| Other Assets | 234 | 322 | 393 | 449 | 542 | 767 |
| Total Assets | 428 | 571 | 666 | 806 | 996 | 1,471 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 32 | 14 | 11 | 72 | 135 | 233 |
| Cash from Investing Activity | -62 | -130 | -76 | -52 | -125 | -392 |
| Cash from Financing Activity | 36 | 121 | 60 | 27 | 54 | 157 |
| Net Cash Flow | 5 | 6 | -4 | 47 | 65 | -2 |
| Free Cash Flow | -29 | -64 | -62 | -8 | 35 | 114 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 101 | 123 | 132 | 131 | 129 | 116 |
| Inventory Days | 65 | 50 | 67 | |||
| Days Payable | 56 | 70 | 63 | |||
| Cash Conversion Cycle | 110 | 103 | 137 | 131 | 129 | 116 |
| Working Capital Days | 26 | 55 | 19 | 56 | 27 | 42 |
| ROCE % | -4 | 1 | 8 | 14 | 15 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
company capacity utilisation %
74.00pct
2026-06-30
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
-346inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
stores / outlets at period end
550count
2026-06-30
volume growth %
13.30pct
2026-06-30
News
News and filings about Nephrocare Health Services Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
- 3B Blackbio Dx Limited
- Dr. Lal Path Labs Ltd.
- Gaudium IVF and Women Health Limited
- Health X Platform Limited
- Krsnaa Diagnostics Limited
- Metropolis Healthcare Limited
- One Global Service Provider Limited
- Pramodini Medicare Limited
- Sastasundar Ventures Limited
- Suraksha Diagnostic Limited
- Thyrocare Technologies Limited
- Vijaya Diagnostic Centre Limited
Uses as raw material
- acid and bicarbonate dialysis concentrates
- blood tubing lines
- dialysers
- heparin
- normal saline
- reverse-osmosis water-treatment membranes
Sells to
- CARE Hospitals · in-hospital dialysis unit operations (unlisted hospital partner)
- Fortis Healthcare Limited · in-hospital dialysis unit operations / haemodialysis services (captive clinic partnership)
- Global Health Limited · in-hospital dialysis unit operations / haemodialysis services (captive clinic partnership)
- Max Healthcare Institute · in-hospital dialysis unit operations / haemodialysis services (captive clinic partnership)
- Ministry of Health, Republic of Uzbekistan · design-build-operate-maintain dialysis centres under PPP
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Healthcare Service Provider
- Classification
- Healthcare › Healthcare Service Provider
- ISIN
- INE428V01029
News impact
Big market events that reach Nephrocare Health Services Limited, and how the effect spreads.
24 Sept, 11:36 IST · Market event · high impact
Nephrocare shares tumble 5% | What’s driving the decline?
Large holders are selling about Rs 650 crore of kidney-care firm Nephrocare at a 5% discount, hurting current shareholders short-term while letting new buyers enter cheaper.
Who it hits first
- Nephrocare Health Services, which runs kidney dialysis clinics, fell over 5% after reports that large holders want to sell about Rs 650 crore of shares at Rs 705 each.
- That Rs 705 price is about 5% below the last close of Rs 741.90, so the market is repricing toward the cheaper deal price.
- The business itself is unchanged — only the shareholding is shifting.
Who may gain
- Buyers who get the block at Rs 705 gain an instant 5% discount to the Rs 741.90 close.
- Patient investors who wanted Nephrocare shares can now buy the dip if the fall overdoes the discount.
Along the supply chain
Downstream
No direct downstream impact — hospitals it serves, including Max Healthcare, Fortis Healthcare, and Medanta, see no change to orders or contracts from this share sale.
Upstream
No direct supply-chain link upstream — Nephrocare lists no suppliers in the pack, and a shareholder sale does not change what it buys.
Where demand moves
Business
No change to patient visits, dialysis sessions, or clinic revenue — the Rs 650 crore sale moves existing shares between investors, not customers.
Capital
About Rs 650 crore of new share supply near Rs 705 pulls the price down short-term as traders sell; bargain hunters absorbing the block provide the offsetting buy flow.
How it spreads across sectors
Healthcare
No sector-wide impact — a single-company share sale with no change to hospital or lab demand; peers should trade flat.
When it plays out
Immediate
1–7 days: Nephrocare trades heavy near Rs 705 as the Rs 650 crore block clears; peers flat.
Medium term
1–6 months: price follows clinic results again, not the block; no lasting sector effect.
Short term
1–4 weeks: discount overhang fades if buyers hold; price stabilises unless more selling appears.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Splits, bonuses & buybacks
- daily-prices repair: 2 rows from NSE's archive (replace 0, delete 1, insert 1), 2026-01-15..2026-02-01 (docs/flat_day_repair.md)1× · 15 Jan 2026
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 24 Sep 2026 | POLAR CAPITAL FUNDS PLC-HEALTHCARE OPPORTUNITIES FUND | BUY | 25,45,719 | ₹705.00 |
| 24 Sep 2026 | EDORAS INVESTMENT HOLDINGS PTE LTD | SELL | 8,42,109 | ₹710.18 |
| 24 Sep 2026 | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | BUY | 8,23,311 | ₹705.24 |
| 24 Sep 2026 | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | SELL | 8,15,776 | ₹710.45 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY2712 Aug 2026
- Annual report · 2025-2616 Jul 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY2620 May 2026
- Earnings call · Q3FY2611 Feb 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.